Tanaproget

Tanaproget
Clinical data

ATC code	none
Legal status
Legal status	Investigational
Identifiers
IUPAC name 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile
CAS Number	304853-42-7
PubChem CID	4369524
DrugBank	DB04787
ChemSpider	3572060
ECHA InfoCard	100.217.016
Chemical and physical data
Formula	C₁₆H₁₅N₃OS
Molar mass	297.375 g/mol
3D model (Jmol)	Interactive image
SMILES CC1(C2=C(C=CC(=C2)C3=CC=C(N3C)C#N)NC(=S)O1)C
InChI InChI=1S/C16H15N3OS/c1-16(2)12-8-10(4-6-13(12)18-15(21)20-16)14-7-5-11(9-17)19(14)3/h4-8H,1-3H3,(H,18,21) Key:PYVFWTPEBMRKSR-UHFFFAOYSA-N

Tanaproget (INN; developmental code names NSP-989, WAY-166989) is an investigational non-steroidal progestin. It is a high affinity, high efficacy, and very selective agonist of the progesterone receptor (PR). Due to its much more selective binding profile relative to most conventional, steroidal progestins, tanaproget may prove to produce fewer side effects in comparison. As of December 2010, it is in phase II clinical trials in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals.